The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | An indirect comparison of taletrectinib and crizotinib in ROS1+ NSCLC
Misako Nagasaka, MD, UCI Health Chao Family Comprehensive Cancer Center, Orange, CA, discusses a matching-adjusted indirect comparison of taletrectinib and crizotinib in TKI-naïve patients with ROS1-positive non-small cell lung cancer (NSCLC), using data from the TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials. Taletrectinib demonstrated higher response rates and significantly reduced the risk of disease progression and mortality compared to crizotinib. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
